Sample Size Calculation for Active-Arm Trial with Counterfactual Incidence Based on Recency Assay

by   Fei Gao, et al.

The past decade has seen tremendous progress in the development of biomedical agents that are effective as pre-exposure prophylaxis (PrEP) for HIV prevention. To expand the choice of products and delivery methods, new medications and delivery methods are under development. Future trials of non-inferiority, given the high efficacy of ARV-based PrEP products as they become current or future standard of care, would require a large number of participants and long follow-up time that may not be feasible. This motivates the construction of a counterfactual estimate that approximates incidence for a randomized concurrent control group receiving no PrEP. We propose an approach that is to enroll a cohort of prospective PrEP users and augment screening for HIV with laboratory markers of duration of HIV infection to indicate recent infections. We discuss the assumptions under which these data would yield an estimate of the counterfactual HIV incidence and develop sample size and power calculations for comparisons to incidence observed on an investigational PrEP agent.


page 1

page 2

page 3

page 4


Designing efficient randomized trials: power and sample size calculation when using semiparametric efficient estimators

Trials enroll a large number of subjects in order to attain power, makin...

A web application for the design of multi-arm clinical trials

Multi-arm designs provide an effective means of evaluating several treat...

Flexible Seamless 2-in-1 Design with Sample Size Adaptation

2-in-1 design (Chen et al. 2018) is becoming popular in oncology drug de...

Bayesian Sample Size Calculations for SMART Studies

In the management of most chronic conditions characterized by the lack o...

On the use of non-concurrent controls in platform trials: A scoping review

Platform trials gained popularity during the last few years as they incr...

On variance estimation for the one-sample log-rank test

Time-to-event endpoints show an increasing popularity in phase II cancer...

Please sign up or login with your details

Forgot password? Click here to reset